Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
Status:
Completed
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
The primary objectives of this study:
- To investigate the safety and tolerability of ascending repeated oral doses of
BAY1902607 in healthy subjects (Part 1).
- To investigate the effect of BAY1902607 on the pharmacokinetics (PK) of a
sub-therapeutic 1 mg dose of midazolam (Part 1).
- To investigate the safety, tolerability and efficacy of BAY1902607 in patients with
refractory chronic cough (Part 2).